The clinical success of Valemetostat, a novel dual inhibitor of EZH1 and EZH2, suggested significant clinical efficacy with a 44% objective response rate in a phase 2 trial involving 119 patients with relapsed or refractory peripheral T-cell lymphoma, establishing EZH inhibition as a promising therapeutic strategy for T-cell malignancies (132). The gene discussed is EZH1; the disease is peripheral T-cell lymphoma, not otherwise specified.